The Latest Cardiac and Vascular News
– Secured access to new capital through debt and equity transactions – Increased utilization of Treprostinil Injection with increasing payer generic mandates – Advanced Hatch-Waxman litigation in support of final regulatory approval of YUTREPIA™ (treprostinil) inhalation powder – Company to host webcast and conference call today at 8:30 a.m. ET […]
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoing LianBio’s partner, Tarsus, announced positive topline data from the Phase 3 Saturn-2 clinical trial […]
TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart Rhythm 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today […]
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc. announces that it has completed patient enrollment in the DEEPER OUS clinical trial (NCT03807531) for the company’s Temporary Spur Stent System, a novel device that features a retrievable stent designed for complex infrapopliteal disease. 106 patients have now been enrolled in the prospective, nonrandomized […]
WEST CHESTER, Pa., May 11, 2022 /PRNewswire/ — VESTECK, Inc. is pleased to announce their participation and strong podium presence at the Charring Cross International Vascular Symposium. “Charring Cross” (CX), held annually in London, UK, is considered one of the premier global Vascular/Endovascular symposiums. Key Opinion Leaders from around the world assemble to […]
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on […]
Increased commercial momentum and great interest in CADScor® System on the US market 2022 has started off positiv with important steps on the US market, recruitment of key staff and continued validation that our business model works. We report doubled sales of patches compared with the corresponding quarter of 2021. […]
SPARKS, Md., May 10, 2022 (GLOBE NEWSWIRE) — TridentCare, a national leader of portable diagnostic services, announces its new partnership with Harness Health Partners to provide mobile X-ray, Ultrasound and EKG services across the United States. “This is an exciting time for TridentCare,” says TridentCare CEO David Velez. “We are excited […]
Westport, CT, May 11, 2022 (GLOBE NEWSWIRE) — To date, Company’s FDA 510(k) cleared PURE EP(TM) system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States The Company adds new executives to accelerate sustained commercial momentum developing a national installed base of the PURE EP […]
NAARDEN, Netherlands & MIAMI–(BUSINESS WIRE)–NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases, today announced the publication of a new meta-analysis in the European Heart Journal’s publication Cardiovascular Pharmacotherapy, discussing the effect of cholesteryl ester transfer protein (CETP) inhibitors on new-onset diabetes. […]
